Rapamycin News and Research

RSS

Rapamycin is a drug used to prevent the rejection of organ and bone marrow transplants by the body. Rapamycin is an antibiotic that blocks a protein involved in cell division and inhibits the growth and function of certain T cells of the immune system involved in the body's rejection of foreign tissues and organs. It is a type of immunosuppressant and a type of serine/threonine kinase inhibitor. Rapamycin is now called sirolimus.

Sirolimus may help treat lymphangioleiomyomatosis in women

An Oregon Health & Science University researcher has co-authored an international study that revealed a drug approved to prevent rejection in organ transplant patients helped treat a rare lung disease in women.

12 Apr 2011

Pfizer to present new investigational compounds data against cancer at AACR meeting

Pfizer Oncology will present nearly 30 abstracts highlighting research in new and established pathways, including inhibition of Hedgehog signaling; dual inhibition of PI3K/mTOR; and cancer stem cell-based targets.

2 Apr 2011

Three abstracts from SuperGen PIM kinase inhibitor program to be presented at AACR

SuperGen, Inc., a pharmaceutical company dedicated to the discovery and development of novel cancer therapies, today announced the acceptance of three abstracts from the SuperGen PIM kinase inhibitor program. Poster presentations by SuperGen and collaborators will occur on April 3 and 5, 2011 at the American Association for Cancer Research 102nd Annual Meeting in Orlando, Florida.

2 Apr 2011

Mutated cancer pathway studies identify therapeutic targets for congenital heart disease

Cross-disciplinary teams of scientists studying genetic pathways that are mutated in many forms of cancer, but which also cause certain forms of congenital heart disease - including hypertrophic cardiomyopathy, a thickening of the heart muscle that is the leading cause of sudden death in children and young adults -, have introduced these mutations into mice and successfully treated HCM in the lab.

22 Feb 2011

New study: Rapamycin reverses cardiac muscle damage in LEOPARD syndrome mouse model

Congenital heart diseases affect approximately one in 100 patients, making them the most common type of birth defect and the number-one cause of pediatric deaths.

21 Feb 2011

Intellikine, PKD Foundation to investigate novel therapies for patients with PKD

Intellikine, a leader in the development of small molecule drugs targeting the PI3K/mTOR pathway, and the PKD Foundation today announced a collaboration to investigate novel, orally-available small molecule kinase inhibitors of the TORC1 and TORC2 complexes as a potential treatment for patients with polycystic kidney disease.

11 Feb 2011

Everolimus phase III study shows improved progression-free survival in patients with pNET

In an international Phase III randomized study, everolimus, an inhibitor of the mammalian target of rapamycin, has shown to dramatically improve progression-free survival for patients with advanced pancreatic neuroendocrine tumors, according to researchers from The University of Texas MD Anderson Cancer Center.

9 Feb 2011

Vascular birthmarks can cause concern for parents: Dermatologists

Vascular birthmarks, which occur in nearly 10 percent of all infants at birth or within the first few weeks of life, can cause concern for parents particularly if they are large or in a cosmetically important area. The decision to treat a birthmark is one that parents should make with a dermatologist, who can determine the type of birthmark and whether or not it poses any potential risks in the future.

5 Feb 2011

Defective nucleoli linked to Parkinson's disease

"Nucleolus", or small nucleus, is the term coined by early biologists for the tiny structure within the nucleus which they saw under the microscope. In this structure within the nucleus, RNA molecules and proteins are assembled to form ribosomes, the true protein factories of cells.

2 Feb 2011

Resveratrol stimulates expression of adiponectin hormone: Study

Resveratrol, a compound in grapes, displays antioxidant and other positive properties. In a study published this week, researchers at the UT Health Science Center San Antonio describe a novel way in which resveratrol exerts these beneficial health effects.

10 Jan 2011

mTORC1 cellular pathway affects aging phenotype

Whitehead Institute researchers have linked hyperactivity in the mechanistic target of rapamycin complex 1 (mTORC1) cellular pathway, to reduced ketone production, which is a well-defined physiological trait of aging in mice.

23 Dec 2010

Merck, sanofi-aventis enter global cancer research and development agreement

Merck Serono, a division of Merck KGaA, Darmstadt, Germany, announced today that Merck, has signed a worldwide research and development agreement with sanofi-aventis U.S. Inc., under which Merck Serono and sanofi-aventis U.S. Inc. will collaboratively investigate novel experimental combinations of agents that could block specific pathways in cancer cells. This collaboration could deliver novel targeted oncology treatments with high therapeutic potential.

17 Dec 2010

John Theurer Cancer Center presents research findings at ASH meeting

The John Theurer Cancer Center at Hackensack University Medical Center announced today important research findings presented at the annual meeting of the American Society of Hematology taking place December 4-7, 2010 in Orlando, Florida. The ASH meeting is the world's leading scientific gathering of hematologists and hematology researchers.

7 Dec 2010

Pfizer's Phase 3 AXIS 1032 trial for metastatic renal cell carcinoma meets primary endpoint

Pfizer Inc. announced today that the Phase 3 AXIS 1032 trial (A4061032), studying the investigational compound axitinib in previously treated patients with metastatic renal cell carcinoma (mRCC), has met its primary endpoint, demonstrating that axitinib significantly extended progression-free survival when compared to sorafenib, in the study population.

20 Nov 2010

Semafore's SF1126 for B-cell chronic lymphocytic leukemia granted FDA orphan drug designation

Semafore Pharmaceuticals announced today that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation to the Company's SF1126 product candidate for the treatment of B-cell chronic lymphocytic leukemia (CLL). In April 2010, the Company initiated an expansion of its ongoing Phase I clinical study into this disease setting. SF1126 is a novel peptidic prodrug that converts to LY294002, one of the most widely studied small molecule inhibitors of both phosphatidylinositol 3-kinase (PI3K) and mammalian target of rapamycin (mTOR).

9 Nov 2010

Xenogenics acquires Ideal BioStent assets

MultiCell Technologies, Inc. and its majority owned subsidiary, Xenogenics Corporation, are pleased to announce the acquisition of the Ideal™ BioStent assets by Xenogenics Corporation from investment funds managed by Western Technology Investment and Silicon Valley Bank. Xenogenics Corporation also entered into a worldwide exclusive license with Rutgers University for rights to certain intellectual property related to the Ideal™ BioStent.

19 Oct 2010

AVEO Pharmaceuticals to present tivozanib Phase 2 study results at IKCS Symposium

AVEO Pharmaceuticals, Inc., a biopharmaceutical company focused on discovering, developing and commercializing cancer therapeutics, today announced that previously reported results from its Phase 2 study evaluating tivozanib for the treatment of advanced renal cell carcinoma (RCC) will be presented at the Ninth International Kidney Cancer Symposium (IKCS) in Chicago, Illinois, October 1-2, 2010.

4 Oct 2010

PET imaging technique helps early treatment response assessment for cisplatin-resistant ovarian cancer

Research reported in the October issue of The Journal of Nuclear Medicine (JNM) shows that a molecular imaging technique may prove useful in early assessment of treatment response for cisplatin-resistant ovarian cancer.

4 Oct 2010

Scientists identify new pathway to control immune balance

St. Jude Children's Research Hospital scientists have identified a new pathway that helps control the immune balance through reciprocal regulation of specialized T lymphocytes, which play very different inflammatory roles.

21 Sep 2010

U-M research results show potential for discovering new avenues for anti-aging drugs

A team of University of Michigan scientists has found that suppressing a newly discovered gene lengthens the lifespan of roundworms. Scientists who study aging have long known that significantly restricting food intake makes animals live longer. But the goal is to find less drastic ways to achieve the same effect in humans someday. The U-M results offer promising early evidence that scientists may succeed at finding targets for drugs that someday could allow people to live longer, healthier lives.

19 Aug 2010

Rapamycin News and Research

Sirolimus may help treat lymphangioleiomyomatosis in women

Pfizer to present new investigational compounds data against cancer at AACR meeting

Three abstracts from SuperGen PIM kinase inhibitor program to be presented at AACR

Mutated cancer pathway studies identify therapeutic targets for congenital heart disease

New study: Rapamycin reverses cardiac muscle damage in LEOPARD syndrome mouse model

Intellikine, PKD Foundation to investigate novel therapies for patients with PKD

Everolimus phase III study shows improved progression-free survival in patients with pNET

Vascular birthmarks can cause concern for parents: Dermatologists

Defective nucleoli linked to Parkinson's disease

Resveratrol stimulates expression of adiponectin hormone: Study

mTORC1 cellular pathway affects aging phenotype

Merck, sanofi-aventis enter global cancer research and development agreement

John Theurer Cancer Center presents research findings at ASH meeting

Pfizer's Phase 3 AXIS 1032 trial for metastatic renal cell carcinoma meets primary endpoint

Semafore's SF1126 for B-cell chronic lymphocytic leukemia granted FDA orphan drug designation

Xenogenics acquires Ideal BioStent assets

AVEO Pharmaceuticals to present tivozanib Phase 2 study results at IKCS Symposium

PET imaging technique helps early treatment response assessment for cisplatin-resistant ovarian cancer

Scientists identify new pathway to control immune balance

U-M research results show potential for discovering new avenues for anti-aging drugs

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

From Puberty to Menopause: Clue’s CEO, Audrey Tsang on the Power of Femtech

Latest News